Related Experiment Video

Updated: Aug 13, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

B-type natriuretic peptide levels in obese patients with advanced heart failure

Tamara B Horwich1, Michele A Hamilton, Gregg C Fonarow

  • 1Ahmanson-UCLA Cardiomyopathy Center, UCLA Division of Cardiology, Los Angeles, California 90095-1679, USA.

Journal of the American College of Cardiology
|January 3, 2006
PubMed

Insights

In heart failure (HF) patients, higher body mass index (BMI) is linked to lower B-type natriuretic peptide (BNP) levels. However, BNP remains a crucial predictor of adverse outcomes across all BMI categories.

Area of Science:

  • Cardiology
  • Biomarkers
  • Obesity Research

Background:

  • Obesity, indicated by elevated body mass index (BMI), is inversely correlated with B-type natriuretic peptide (BNP) levels in general and heart failure (HF) populations.
  • The impact of BMI on the prognostic utility of BNP in HF patients remains incompletely understood.

Purpose of the Study:

  • To investigate how obesity influences the predictive power of B-type natriuretic peptide (BNP) assays in patients diagnosed with heart failure (HF).

Main Methods:

  • Analysis of data from 316 patients with systolic heart failure (left ventricular ejection fraction ≤40%).
  • Patients were stratified into BMI categories: lean (<25 kg/m²), overweight (25–29.9 kg/m²), and obese (≥30 kg/m²).

Main Results:

  • BNP levels were significantly lower in overweight and obese patients compared to lean patients (median BNP: 747, 380, and 332 pg/ml, respectively).
  • Elevated BNP correlated with worse symptoms and higher pulmonary capillary wedge pressure across all BMI groups.
  • Higher BNP independently predicted survival, with optimal cutoffs varying by BMI category (590, 471, and 342 pg/ml for lean, overweight, and obese, respectively).

Conclusions:

  • Despite lower circulating levels in overweight and obese individuals, BNP effectively predicts worse symptoms, impaired hemodynamics, and increased mortality in heart failure patients.
  • BNP retains its prognostic value across the spectrum of BMI in heart failure management.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...